Efficacy of pharmacogenetic (PGx)-guided antidepressant treatment on functional outcomes and quality of life in adults with anxiety and affective disorders: A systematic review and meta-analysis

We conducted a systematic review and meta-analysis to estimate the efficacy of pharmacogenetic (PGx)-guided antidepressant treatment compared to treatment as usual (TAU) on functional outcomes and quality of life (QoL) in people with anxiety and affective disorders. A PRISMA-compliant systematic sea...

Descripción completa

Detalles Bibliográficos
Autores: Fares Otero, Natalia Elena, Budde, Monika, Laatsch, Jonathan, Harrer, Mathias, Pelgrim, Teuntje A. D, Philipsen, Alexandra, Heilbronner, Urs, Vieta i Pascual, Eduard, 1963-, Westrhenen, Roos van, PSY-PGx Consortium
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2025
País:España
Institución:Universidad de Barcelona
Repositorio:Dipòsit Digital de la UB
OAI Identifier:oai:diposit.ub.edu:2445/223053
Acceso en línea:https://hdl.handle.net/2445/223053
Access Level:acceso abierto
Palabra clave:Antidepressius
Trastorns afectius
Ansietat
Antidepressants
Affective disorders
Anxiety
id ES_2cbc39d5384f6eb3f03a67251cb03100
oai_identifier_str oai:diposit.ub.edu:2445/223053
network_acronym_str ES
network_name_str España
repository_id_str
spelling Efficacy of pharmacogenetic (PGx)-guided antidepressant treatment on functional outcomes and quality of life in adults with anxiety and affective disorders: A systematic review and meta-analysisFares Otero, Natalia ElenaBudde, MonikaLaatsch, JonathanHarrer, MathiasPelgrim, Teuntje A. DPhilipsen, AlexandraHeilbronner, UrsVieta i Pascual, Eduard, 1963-Westrhenen, Roos vanPSY-PGx ConsortiumAntidepressiusTrastorns afectiusAnsietatAntidepressantsAffective disordersAnxietyWe conducted a systematic review and meta-analysis to estimate the efficacy of pharmacogenetic (PGx)-guided antidepressant treatment compared to treatment as usual (TAU) on functional outcomes and quality of life (QoL) in people with anxiety and affective disorders. A PRISMA-compliant systematic search was performed up to 26/06/2025 to identify relevant prospective, randomised controlled trials (RCTs) in seven databases. The revised tool for Risk of Bias (RoB2) was used to assess the methodological qualities of the included studies (PROSPERO CRD42024518683). Of 2774 records, six studies were included comprising 2285 adult patients (PGx group: n = 1395, Mean age = 48.14 years; 55.68 % females; TAU group: n = 890, Mean age = 47.83 years, 58.22 % females). Three studies were included in random-effect meta-analyses. In these, PGx-guided antidepressant treatment significantly decreased functional disability, measured by the Sheehan Disability Scale/Inventory (SDS/I), compared to TAU (k = 3, Mean Difference = -2.85, SE = 1.32 [95 % CI: -5.44, -0.26], p = .031). The Hartung-Knapp adjustment of p-values yielded non-significant effects. Individually, one of these three studies reported a significant effect of PGx-guided treatment on overall SDS score, one on SDI Perceived Social Support partial score, and one no effect. Risk for bias was rated high for one study, with some concerns for the other five. Due to the small number of included trials, our ability to conduct analyses of heterogeneity, moderators and publication bias was limited. Nonetheless, our results suggest that PGx-guided antidepressant treatment may improve functioning in people with anxiety and affective disorders.Elsevier B.V.2025info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://hdl.handle.net/2445/223053Articles publicats en revistes (Medicina)reponame:Dipòsit Digital de la UBinstname:Universidad de BarcelonaInglésReproducció del document publicat a: https://doi.org/10.1016/j.euroneuro.2025.08.003European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2025, vol. 100, p. 13-23https://doi.org/10.1016/j.euroneuro.2025.08.003cc-by (c) Fares Otero, Natalia Elena et al., 2025http://creativecommons.org/licenses/by/3.0/es/info:eu-repo/semantics/openAccessoai:diposit.ub.edu:2445/2230532026-05-27T06:46:51Z
dc.title.none.fl_str_mv Efficacy of pharmacogenetic (PGx)-guided antidepressant treatment on functional outcomes and quality of life in adults with anxiety and affective disorders: A systematic review and meta-analysis
title Efficacy of pharmacogenetic (PGx)-guided antidepressant treatment on functional outcomes and quality of life in adults with anxiety and affective disorders: A systematic review and meta-analysis
spellingShingle Efficacy of pharmacogenetic (PGx)-guided antidepressant treatment on functional outcomes and quality of life in adults with anxiety and affective disorders: A systematic review and meta-analysis
Fares Otero, Natalia Elena
Antidepressius
Trastorns afectius
Ansietat
Antidepressants
Affective disorders
Anxiety
title_short Efficacy of pharmacogenetic (PGx)-guided antidepressant treatment on functional outcomes and quality of life in adults with anxiety and affective disorders: A systematic review and meta-analysis
title_full Efficacy of pharmacogenetic (PGx)-guided antidepressant treatment on functional outcomes and quality of life in adults with anxiety and affective disorders: A systematic review and meta-analysis
title_fullStr Efficacy of pharmacogenetic (PGx)-guided antidepressant treatment on functional outcomes and quality of life in adults with anxiety and affective disorders: A systematic review and meta-analysis
title_full_unstemmed Efficacy of pharmacogenetic (PGx)-guided antidepressant treatment on functional outcomes and quality of life in adults with anxiety and affective disorders: A systematic review and meta-analysis
title_sort Efficacy of pharmacogenetic (PGx)-guided antidepressant treatment on functional outcomes and quality of life in adults with anxiety and affective disorders: A systematic review and meta-analysis
dc.creator.none.fl_str_mv Fares Otero, Natalia Elena
Budde, Monika
Laatsch, Jonathan
Harrer, Mathias
Pelgrim, Teuntje A. D
Philipsen, Alexandra
Heilbronner, Urs
Vieta i Pascual, Eduard, 1963-
Westrhenen, Roos van
PSY-PGx Consortium
author Fares Otero, Natalia Elena
author_facet Fares Otero, Natalia Elena
Budde, Monika
Laatsch, Jonathan
Harrer, Mathias
Pelgrim, Teuntje A. D
Philipsen, Alexandra
Heilbronner, Urs
Vieta i Pascual, Eduard, 1963-
Westrhenen, Roos van
PSY-PGx Consortium
author_role author
author2 Budde, Monika
Laatsch, Jonathan
Harrer, Mathias
Pelgrim, Teuntje A. D
Philipsen, Alexandra
Heilbronner, Urs
Vieta i Pascual, Eduard, 1963-
Westrhenen, Roos van
PSY-PGx Consortium
author2_role author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Antidepressius
Trastorns afectius
Ansietat
Antidepressants
Affective disorders
Anxiety
topic Antidepressius
Trastorns afectius
Ansietat
Antidepressants
Affective disorders
Anxiety
description We conducted a systematic review and meta-analysis to estimate the efficacy of pharmacogenetic (PGx)-guided antidepressant treatment compared to treatment as usual (TAU) on functional outcomes and quality of life (QoL) in people with anxiety and affective disorders. A PRISMA-compliant systematic search was performed up to 26/06/2025 to identify relevant prospective, randomised controlled trials (RCTs) in seven databases. The revised tool for Risk of Bias (RoB2) was used to assess the methodological qualities of the included studies (PROSPERO CRD42024518683). Of 2774 records, six studies were included comprising 2285 adult patients (PGx group: n = 1395, Mean age = 48.14 years; 55.68 % females; TAU group: n = 890, Mean age = 47.83 years, 58.22 % females). Three studies were included in random-effect meta-analyses. In these, PGx-guided antidepressant treatment significantly decreased functional disability, measured by the Sheehan Disability Scale/Inventory (SDS/I), compared to TAU (k = 3, Mean Difference = -2.85, SE = 1.32 [95 % CI: -5.44, -0.26], p = .031). The Hartung-Knapp adjustment of p-values yielded non-significant effects. Individually, one of these three studies reported a significant effect of PGx-guided treatment on overall SDS score, one on SDI Perceived Social Support partial score, and one no effect. Risk for bias was rated high for one study, with some concerns for the other five. Due to the small number of included trials, our ability to conduct analyses of heterogeneity, moderators and publication bias was limited. Nonetheless, our results suggest that PGx-guided antidepressant treatment may improve functioning in people with anxiety and affective disorders.
publishDate 2025
dc.date.none.fl_str_mv 2025
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/2445/223053
url https://hdl.handle.net/2445/223053
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Reproducció del document publicat a: https://doi.org/10.1016/j.euroneuro.2025.08.003
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2025, vol. 100, p. 13-23
https://doi.org/10.1016/j.euroneuro.2025.08.003
dc.rights.none.fl_str_mv cc-by (c) Fares Otero, Natalia Elena et al., 2025
http://creativecommons.org/licenses/by/3.0/es/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv cc-by (c) Fares Otero, Natalia Elena et al., 2025
http://creativecommons.org/licenses/by/3.0/es/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Elsevier B.V.
publisher.none.fl_str_mv Elsevier B.V.
dc.source.none.fl_str_mv Articles publicats en revistes (Medicina)
reponame:Dipòsit Digital de la UB
instname:Universidad de Barcelona
instname_str Universidad de Barcelona
reponame_str Dipòsit Digital de la UB
collection Dipòsit Digital de la UB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869405261534330880
score 15,811543

Similares en LA Referencia